Chromosome band 9p21-22 is one of the most common targets tumors, albeit less frequently in the latter. 9 Moreover, inactiv- (PCR) assay to accurately define the size of the 9p21-22 deletions in primary and secondary acute lymphoid leukemias. We have also searched for deletions at the IFN␣ and ␤ genes and the p15 gene aiming to clarify the role of these Introduction genes in leukemias with and without p16 deletions.
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The disruption of oncogenes or inactivation of tumor suppressor genes play a central role in the pathogenesis of malignant diseases; such abnormalities may be associated with visMaterials and methods ible chromosomal translocations or deletions. In leukemia, detailed characterization of non-randon chromosome changes Patients and cell lines has provided a basis for disease classification and has helped to define prognosis in individual patients. The identification Eighteen patients with de novo ALL and 12 patients with of the genes involved in the chromosomal changes has chronic myloid leukemia in lymphoid blast crisis (CML-BC-L) advanced our understanding of the mechanisms of leukemowere studied. The p16 status of most of these cases has been genesis and has been valuable in the design of molecular reported previously. 23, 24 Leukemia cell phenotypes were approaches to diagnosis and to monitoring response to determined morphologically and by conventional cytochemitreatment.
stry and immunologic methods. Cytogenetics analysis was Chromsome band 9p21-22 is one of the most common performed in most cases. All CML cases were BCR-ABL positargets for translocations and deletions in cancer. 1 Initial tive. All leukemic samples analyzed had more than 50% blast observations characterized deletions in this region in acute cells. Constitutional DNA from buccal epithelial cells, lymphoblastic leukemia (ALL), 2 glioma, 3 lung cancer 4 and remission DNA, or chronic-phase DNA was available for most bladder tumor. 5 In addition, linkage studies pointed to a gene individuals. Nine leukemia/lymphoma cell lines were also in this area responsible for familial and sporadic melanoma. investigated: BV173, K562, KCL22, KU812, HL60, JVM13, The type-I interferon gene (IFN) cluster maps to 9p21-22 and SD1, LAMA84 and RIVA. was originally suggested as the target for deletions in lymphoid leukemias. 2 However, more recently another candidate target, the p16/CDKN2 tumor suppressor gene, was identified DNA preparation and multiplex PCR within this commonly deleted region. 7, 8 The p16 gene is frequently homozygously deleted in tumor cell lines and primary Mononuclear cells were isolated from heparinized peripheral blood or bone marrow samples by density gradient centrifugation, and genomic DNA was extracted as previously described. We have analyzed 10 genes/markers at 9p21-22, ie IFN␤,
Figure 2
Duplex PCR analysis of the p16 and p15 genes in leukemia cell lines. Lanes marked 0% to 100% are standards for 9p21-22 loss constructed as described in the Methods. See Figure 1a for correspondencing diagram of deletions found in the samples shown here. An image of the gel was captured using a CCD camera linked to a frame grabber (UVP, Cambridge, UK) and band intensities c). Because all patient samples contained normal cells that would give rise to a normal 'target' sequence product, a semiquantified using the program NIH Image 1.55 (NIH, Bethesda, MD, USA). Using this multiplex PCR assay, we did not attempt quantitative multiplex PCR was performed in which a 'target' sequence was coamplified with at least two different unrelated to discern hemizygous deletions in the patient samples due to variable percentages of normal contaminating cells. sequences, in separate reactions. The unrelated sequence serves as an internal control for the total amount (leukemic However, for cell lines we were able to detect deletion of just one allele. and non-leukemic) of DNA in each sample; the presence or absence of a deletion encompassing the target sequence is determined by comparing the relative intensity of target and control bands and reference to standards. Standards were conLoss of heterozygosity analysis structed by mixing normal DNA and K562 DNA, which is homozygously deleted for all markers analyzed at 9p21-22, LOH analysis was performed by PCR amplification of a dinucleotide repeat polymorphism at the IFN␣ locus 25 (See Table 2 simulating 9p21-22 loss of 25, 50, 75 and 100%. Amplification of these standards was performed on each occasion for PCR conditions) in 12 patients for whom we had both constitutive and tumor DNA. The PCR products were verified that the samples were analyzed. The anonymous markers D11S935, D6S281 and D3S1029, the exon 4 of the p53 in a 1.5% ethidium bromide stained agarose gel and all reactions were radiolabeled with three additional PCR cycles congene (p53.4), and a tetranucleotide repeat from the human tyrosine hydroxylase gene (TH) were used as 'control' taining radioactive ␣-32 P d-CTP, as described. 24 The radiolabeled PCR products were denatured at 95°C for 5 min, loaded sequences.
PCR amplifications were performed with 50 ng of genomic onto an 8% denaturing polyacrylamide gel and run for 2 h at 1000 V. The gel was vacuum dried and exposed to Kodak DNA with conditions depending upon the combination of target/control sequences being analyzed (see Tables 1 and 2 (Cambridge, UK) X-Omat film for 12 h. Germline status of patients were determined by amplifying for description of primers sequences and PCR set-up, respectively). Careful experiments were performed to establish buccal epithelial cells or chronic phase DNA in ALL and CML, respectively. Absence or significant reduction in signal of one allele relative to the other in the tumor sample was visually showed homozygous or hemizygous deletion of at least one of the markers/genes analyzed (Figures 1a and 2) . A large mately 1 Mb towards the centromere to include the STS2 date target for deletions at 9p21-22 in ALL and leukemia cell lines. 2, 26 It was deleted in 43% of leukemia cell lines and in marker. In all cases that had homozygous loss at chromosome band 9p21-22, the deletion was restricted to the blast crisis 29% of the primary leukemia samples, although homozygous deletions were reported in less than 10% of the primary DNA; all markers were retained in the chronic phase sample (data not shown).
tumors. 2 The IFN cluster was subsequently shown to be hemizygously deleted in many other tumor types 4,9 but it was regarded more as a marker for LOH at 9p21-22 rather than the actual target of deletions. We have confirmed that the IFN ALL samples:
Seven of the 18 ALL patients studied (38.8%) showed homozygous deletions of chromosome band cluster is rarely homozygously deleted in ALL and lymphoid blast crisis of CML, compared to the frequency of p16 9p21-22 (Figures 1b and 3 ). All seven patients had deletions of the p16 gene (exons 1 and 2). In six cases (33.3%) the STS3 deletions. In cases where the IFN gene cluster is lost, the deletion is always large and encompasses the p16 gene. These marker was also homozygously deleted. As in the CML BC samples, in a minority of cases, (one of 18, 5.5%), the IFN findings support the idea that the IFN gene cluster is deleted as an innocent bystander and not the actual target for deletions at gene cluster was also deleted. The p15 gene was deleted in four cases (22.2%), and the STS2 marker in three cases 9p21-22 in lymphoid neoplasms. In solid tumors, the incidence of LOH at 9p21 is higher (16.6%). The STS1 marker was not deleted in any of the CML or ALL cases.
than the combination of homozygous deletion and inactivating point mutations of p16 in the same group of patients. 9 Although in our study the number of informative cases was relatively small, we did not find evidence for LOH at 9p21-LOH analysis:
Five of the 12 (41.6%) cases analyzed for loss of heterozygosity were informative. One of them (20%), 22 without p16 inactivation. The only patient positive for LOH at the INF␣ locus had a homozygous deletion of p16. a CML case with p16 deletion, showed LOH at the IFN␣ locus.
The deletion map we constructed implicates a minimal region of deletion that includes p16 and extends approximately 400 kb to the telomere (STS3 marker). The data presented here support the fact that p16 is the most frequently homozygously deleted marker within 9p21 in leukeDiscussion mias and that p15 is probably not a second target in this area. Furthermore, our data accord with previous obserWe have constructed a detailed map of homozygous deletions at chromosome band 9p21 in primary and secondary acute vations obtained by FISH and microsatellite analysis, 14, 19, 27 regarding the location and the approximate extension of the lymphoblastic leukemias. We have identified the SRO of deletions in an area of approximately 400 kb which includes critical area of deletion at 9p21. Recently, a new transcript derived from the p16 gene has been described. 28, 29 It the p16 gene but does not include the IFN gene cluster or the p15 gene. We have not observed any important difference includes the p16 exons 2 and 3 and a new, alternative, exon 1 (1␤), located close to the p15 locus. This alternative nuclebetween the pattern of deletions observed in ALL and CML in lymphoid blastic crisis. Interestingly, in the cell lines anaotide sequence has been shown to encode a protein called p19 ARF that is capable of inducing cell cycle arrest. 30 About lyzed, the deletions tended to cluster around the p16 and p15 loci (Figures 1a and 2 ). This finding supports the suggestion 60% of p16 mutations also alter the coding sequence of p19 ARF . 30 It is possible therefore that inactivation of p19 ARF that inactivation of p16 could be a late event that gives growth advantage in tissue culture. enables a more focused search for other putative tumor 210-212. suppressor gene at 9p21 which could be relevant to leukemo- 
